Skip to main content
. 2011 Sep 2;50(11):2093–2099. doi: 10.1093/rheumatology/ker295

Fig. 2.

Fig. 2

Remission rates (%) by criteria for toclizumab vs TNF inhibitor groups (first-line users). Pract Boolean: Boolean remission criterion for clinical practice; Trial Boolean: Boolean remission criterion for clinical trials; TCZ: tocilizumab; TNFi: TNF inhibitors.